{"id":246014,"date":"2012-05-23T15:13:28","date_gmt":"2012-05-23T15:13:28","guid":{"rendered":"http:\/\/www.eugenesis.com\/amp-developing-a-cptr-coding-proposal-for-next-generation-sequencing\/"},"modified":"2012-05-23T15:13:28","modified_gmt":"2012-05-23T15:13:28","slug":"amp-developing-a-cptr-coding-proposal-for-next-generation-sequencing","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/pathology\/amp-developing-a-cptr-coding-proposal-for-next-generation-sequencing.php","title":{"rendered":"AMP Developing a CPT(r) Coding Proposal for Next Generation Sequencing"},"content":{"rendered":"<p><p>    Newswise  Bethesda, MD, May 22, 2012: The Association for    Molecular Pathology (AMP) today announced that it is close to    finalizing a framework proposal for CPT coding of Next    Generation Sequencing (NGS) assays. These technologies make it    possible to deliver large amounts of genomic information at    reasonable cost on panels of genes up to whole exomes and    genomes. Clinical testing using NGS has begun to be offered by    early adopters and is being explored by many academic medical    centers and reference laboratories given the rapidly expanding    array of scientific and clinical studies. These developments    emphasize the importance of incorporating NGS services into the    CPT coding system to assist payers in understanding what    testing has been performed and to make coverage decisions.  <\/p>\n<p>    AMPs expertise in the technical aspects and clinical impact    of molecular testing and the success it has had with previous    molecular CPT coding proposals uniquely positions it to address    CPT coding for Next Generation Sequencing, said Jeffrey Kant,    MD, PhD, Chair of AMPs Economic Affairs Committee.  <\/p>\n<p>    The Committee plans to complete its proposal by the end of June    and release it for feedback from stakeholders in the laboratory    and payer community before submitting a formal proposal to the    AMA CPT Editorial Panel.  <\/p>\n<p>    Iris Schrijver, MD, President of AMP stated, AMP members have    been involved with the development and application of NGS    technologies since their inception. We are proud to provide    leadership in this area as well as to collaborate with other    professional associations to bring these powerful tools to    patient care.  <\/p>\n<p>    CPT is a registered trademark of the American Medical    Association.  <\/p>\n<p>    ABOUT AMP:    The Association for Molecular Pathology (AMP) is an    international medical professional association dedicated to the    advancement, practice, and science of clinical molecular    laboratory medicine and translational research based on the    applications of molecular biology, genetics, and genomics. For    more information, please visit <a href=\"http:\/\/www.amp.org\" rel=\"nofollow\">http:\/\/www.amp.org<\/a>.  <\/p>\n<p>    ###<\/p>\n<\/p>\n<p>Originally posted here:<br \/>\n<a target=\"_blank\" href=\"http:\/\/www.newswise.com\/articles\/view\/589633\/?sc=rssn\" title=\"AMP Developing a CPT(r) Coding Proposal for Next Generation Sequencing\">AMP Developing a CPT(r) Coding Proposal for Next Generation Sequencing<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> Newswise Bethesda, MD, May 22, 2012: The Association for Molecular Pathology (AMP) today announced that it is close to finalizing a framework proposal for CPT coding of Next Generation Sequencing (NGS) assays. These technologies make it possible to deliver large amounts of genomic information at reasonable cost on panels of genes up to whole exomes and genomes <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/pathology\/amp-developing-a-cptr-coding-proposal-for-next-generation-sequencing.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":57,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[577487],"tags":[],"class_list":["post-246014","post","type-post","status-publish","format-standard","hentry","category-pathology"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/246014"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/57"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=246014"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/246014\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=246014"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=246014"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=246014"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}